You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞普生物(300119.SZ):全資子公司獲得名為”必服康“的獸藥產品批准文號
格隆匯 05-28 20:34

格隆匯5月28日丨瑞普生物(300119.SZ)公佈,全資子公司瑞普(保定)生物藥業有限公司近日獲得由農業農村部核發的獸藥產品批準文號。具體如下:

企業名稱:瑞普(保定)生物藥業有限公司

商品名稱:必服康

通用名稱:牛傳染性鼻氣管炎滅活疫苗(C1株)

批准文號:獸藥生字030383018

有效期:2020-04-30至2025-04-29

牛傳染性鼻氣管炎(IBR)是由牛皰疹病毒Ⅰ型引起的一種急性、熱性、接觸性傳染病,以高熱、呼吸困難、鼻炎和上呼吸道炎症為主要特徵。目前國內市場上除揚州優邦的牛病毒性腹瀉/粘膜病、傳染性鼻氣管炎二聯滅活疫苗(NMG株+LY株)外,尚無其他企業生產和銷售IBR商品化疫苗。

牛傳染性鼻氣管炎滅活疫苗(C1株)是由瑞普(保定)生物藥業有限公司與北京生泰爾科技股份有限公司等單位聯合研發,疫苗毒株為國內流行的牛傳染性鼻氣管炎病毒C1株,具有良好的免疫原性,適用於國內牛傳染性鼻氣管炎疫病防控;該疫苗採用水包油603佐劑,具有副反應小、緩釋時間長、粘度低等優點。

該項新產品生產批文的獲得,健全和完善了公司家畜用疫苗產品種類,有助於提高公司的核心競爭力及市場份額,為公司業績提供新的增長點。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account